Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 2/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.40 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.40 |
| ▸ | ACLY | P53396 | 3/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.36 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22005067 | 0.78 | NOTUM (0.50) | HSD17B3NOTUMUSP30UCHL1ACLY | |
| SCHEMBL17806206 | 0.78 | KDM1A (0.48) | NOTUMBRD4 | |
| SCHEMBL14531012 | 0.77 | XIAP (0.45) | HRH3 | |
| SCHEMBL1102007 | 0.77 | ALDH1A1 (0.48) | NOTUMTSHR | |
| SCHEMBL10092850 | 0.76 | ALDH1A1 (0.46) | NOTUMHDAC1HDAC6HPGDTSHR | |
| SCHEMBL24721757 | 0.75 | NLRP3 (0.40) | HSD17B3NOTUMACLYHDAC1HDAC6 | |
| SCHEMBL10092725 | 0.75 | XIAP (0.41) | NOTUMHPGD | |
| SCHEMBL19675746 | 0.75 | ATAD2 (0.40) | HSD17B3NOTUMBRD4 | |
| SCHEMBL10311201 | 0.75 | CHRM2 (0.42) | NOTUM | |
| SCHEMBL13180804 | 0.75 | HTR2A (0.56) | HSD17B3NOTUMTSHRHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | ACLY, ATP5ME, ATP5MG | HSD17B3 2365/4885NOTUM 143/4885USP30 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.